
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9343484/publications.pdf Version: 2024-02-01



CLAUDIA FARIANI

#	Article	IF	CITATIONS
1	Pediatric Scleritis: An Update. Ocular Immunology and Inflammation, 2023, 31, 175-184.	1.0	4
2	Anakinra effectiveness in refractory polyserositis: An Italian multicenter study. Joint Bone Spine, 2022, 89, 105299.	0.8	4
3	Inflammatory muscle involvement in systemic vasculitis: A systematic review. Autoimmunity Reviews, 2022, 21, 103029.	2.5	12
4	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Uveitis. Ophthalmology and Therapy, 2022, 11, 899-911.	1.0	14
5	Development and Implementation of the AIDA International Registry for Patients with Non-Infectious Scleritis. Ophthalmology and Therapy, 2022, 11, 887-897.	1.0	9
6	Development and Implementation of the AIDA International Registry for Patients With Still's Disease. Frontiers in Medicine, 2022, 9, 878797.	1.2	9
7	Validity of Machine Learning in Predicting Giant Cell Arteritis Flare After Glucocorticoids Tapering. Frontiers in Immunology, 2022, 13, 860877.	2.2	9
8	Doppler and Spectral Ultrasound of Sacroiliac Joints in Pediatric Patients with Suspected Juvenile Spondyloarthritis. Diagnostics, 2022, 12, 992.	1.3	2
9	Adalimumab for refractory idiopathic scleritis in children Clinical and Experimental Rheumatology, 2022, , .	0.4	0
10	Development and implementation of the AIDA International Registry for patients with Behçet's disease. Internal and Emergency Medicine, 2022, 17, 1977-1986.	1.0	11
11	Anakinra and canakinumab for patients with R92Q-associated autoinflammatory syndrome: a multicenter observational study from the AIDA Network. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110371.	1.2	1
12	Effectiveness of SB5, an Adalimumab Biosimilar, in Patients With Noninfectious Uveitis: A Real-Life Monocentric Experience. Asia-Pacific Journal of Ophthalmology, 2021, 10, 360-365.	1.3	14
13	Clinical profile and evolution of patients with juvenile-onset Behçet's syndrome over a 25-year period: insights from the AIDA network. Internal and Emergency Medicine, 2021, 16, 2163-2171.	1.0	8
14	Drug survival of anakinra and canakinumab in monogenic autoinflammatory diseases: observational study from the International AIDA Registry. Rheumatology, 2021, 60, 5705-5712.	0.9	4
15	Role of Adalimumab Biosimilar in the Treatment of Non-Anterior Uveitis Associated with Behçet's Syndrome. Ophthalmology and Therapy, 2021, 10, 1129-1135.	1.0	8
16	Biologic Therapies and Small Molecules for the Management of Non-Infectious Scleritis: A Narrative Review. Ophthalmology and Therapy, 2021, 10, 777-813.	1.0	11
17	The Presence of Uveitis Is Associated with a Sustained Response to the Interleukin (IL)-1 Inhibitors Anakinra and Canakinumab in Behçet's Disease. Ocular Immunology and Inflammation, 2020, 28, 298-304.	1.0	46
18	Treating juvenile idiopathic arthritis (JIA)-related uveitis beyond TNF-α inhibition: a narrative review. Clinical Rheumatology, 2020, 39, 327-337.	1.0	12

#	Article	IF	CITATIONS
19	The current status of biological treatment for uveitis. Expert Review of Clinical Immunology, 2020, 16, 787-811.	1.3	15
20	Long-Term Outcomes of Behçet's Syndrome-Related Uveitis: A Monocentric Italian Experience. Mediators of Inflammation, 2020, 2020, 1-8.	1.4	12
21	Adalimumab effectively controls both anterior and posterior noninfectious uveitis associated with systemic inflammatory diseases: focus on Behçet's syndrome. Inflammopharmacology, 2020, 28, 711-718.	1.9	19
22	Behçet's syndrome in Italy: a detailed retrospective analysis of 396 cases seen in 3 tertiary referral clinics. Internal and Emergency Medicine, 2020, 15, 1031-1039.	1.0	13
23	Long-Term Effectiveness of Secukinumab in Patients with Axial Spondyloarthritis. Mediators of Inflammation, 2020, 2020, 1-5.	1.4	20
24	New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators of Inflammation, 2020, 2020, 1-6.	1.4	15
25	Efficacy of monoclonal anti-tumour necrosis factor-α antibodies in uveitic macular oedema. Clinical and Experimental Rheumatology, 2020, 38, 621-625.	0.4	0
26	Effectiveness of TNF-α blockade in the treatment of refractory non-infectious scleritis: a multicentre study. Clinical and Experimental Rheumatology, 2020, 38, 1138-1144.	0.4	4
27	Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients. Clinical Rheumatology, 2019, 38, 407-415.	1.0	56
28	Anakinra Drug Retention Rate and Predictive Factors of Long-Term Response in Systemic Juvenile Idiopathic Arthritis and Adult Onset Still Disease. Frontiers in Pharmacology, 2019, 10, 918.	1.6	25
29	Adalimumab Accounts for Long-Term Control of Noninfectious Uveitis Also in the Absence of Concomitant DMARD Treatment: A Multicenter Retrospective Study. Mediators of Inflammation, 2019, 2019, 1-8.	1.4	27
30	The Role of Biosimilars in Uveitis: Long-Term Real-World Outcomes of the Switch From Original to Biosimilar TNF-Alpha Inhibitors. Frontiers in Pharmacology, 2019, 10, 1468.	1.6	19
31	Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease. Annals of the Rheumatic Diseases, 2019, 78, 1736-1737.	0.5	21
32	Rapid and Sustained Efficacy of Golimumab in the Treatment of Multirefractory Uveitis Associated with Behçet's Disease. Ocular Immunology and Inflammation, 2019, 27, 58-63.	1.0	40
33	Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis. Ocular Immunology and Inflammation, 2019, 27, 34-39.	1.0	37
34	Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis. Clinical Rheumatology, 2019, 38, 63-70.	1.0	29
35	Efficacy of anti-tumour necrosis factor-α monoclonal antibodies in patients with non-infectious anterior uveitis. Clinical and Experimental Rheumatology, 2019, 37, 301-305.	0.4	8
36	Efficacy and safety of certolizumab pegol and golimumab in the treatment of non-infectious uveitis. Clinical and Experimental Rheumatology, 2019, 37, 680-683.	0.4	19

#	Article	IF	CITATIONS
37	Adalimumabâ€Based Treatment Versus Diseaseâ€Modifying Antirheumatic Drugs for Venous Thrombosis in Behçet's Syndrome. Arthritis and Rheumatology, 2018, 70, 1500-1507.	2.9	57
38	Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab. Clinical Rheumatology, 2018, 37, 1715-1720.	1.0	21
39	Biological therapies for the treatment of Behçet's disease-related uveitis beyond TNF-alpha blockade: a narrative review. Rheumatology International, 2018, 38, 25-35.	1.5	15
40	Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study. British Journal of Ophthalmology, 2018, 102, 637-641.	2.1	44
41	Efficacy of adalimumab and infliximab in recalcitrant retinal vasculitis inadequately responsive to other immunomodulatory therapies. Clinical Rheumatology, 2018, 37, 2805-2809.	1.0	35
42	Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clinical Rheumatology, 2018, 37, 2233-2240.	1.0	64
43	Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis. Frontiers in Pharmacology, 2018, 9, 1526.	1.6	15
44	Correlation of Serum Amyloid-A Levels, Clinical Manifestations, Treatment, and Disease Activity in Patients with Behçet's Disease. Israel Medical Association Journal, 2018, 20, 517-521.	0.1	3
45	Prompt Clinical Response to Secukinumab in Patients with Axial Spondyloarthritis: Real Life Observational Data from Three Italian Referral Centers. Israel Medical Association Journal, 2018, 20, 438-441.	0.1	7
46	Epidemiological profile of non-infectious uveitis from the rheumatologist's perspective: a survey from two tertiary referral centres in Italy. Clinical and Experimental Rheumatology, 2018, 36, 68-73.	0.4	15
47	Serum immunoglobulin D levels in patients with Behçet's disease according to different clinical manifestations. Clinical and Experimental Rheumatology, 2018, 36, 110-115.	0.4	8
48	The emerging role of interleukin (IL)-1 in the pathogenesis and treatment of inflammatory and degenerative eye diseases. Clinical Rheumatology, 2017, 36, 2307-2318.	1.0	35
49	Certolizumab Pegol treatment in Behcet's disease with different organ involvement: A multicenter retrospective observational study. Modern Rheumatology, 2017, 27, 1031-1035.	0.9	38
50	The diagnostic evaluation of patients with a suspected hereditary periodic fever syndrome: experienceÂfromÂa referral center in Italy. Internal and Emergency Medicine, 2017, 12, 605-611.	1.0	13
51	Long-term efficacy and safety of golimumab in the treatment of multirefractory Behçet's disease. Clinical Rheumatology, 2017, 36, 2063-2069.	1.0	36
52	Quality of life impairment in Behçet's disease and relationship with disease activity: a prospective study. Internal and Emergency Medicine, 2017, 12, 947-955.	1.0	46
53	IL-6 blockade in the management of non-infectious uveitis. Clinical Rheumatology, 2017, 36, 1459-1469.	1.0	33
54	Systemic Steroid Sparing Effect of Intravitreal Dexamethasone Implant in Chronic Noninfectious Uveitic Macular Edema. Journal of Ocular Pharmacology and Therapeutics, 2017, 33, 549-555.	0.6	11

#	Article	IF	CITATIONS
55	Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 191-197.	1.0	115
56	Longâ€ŧerm efficacy and safety of the interleukinâ€1 inhibitors anakinra and canakinumab in refractory Behŧet disease uveitis and concomitant bladder papillary carcinoma. Internal Medicine Journal, 2017, 47, 1086-1088.	0.5	11
57	Efficacy and safety of adalimumab in Behçet's disease-related uveitis: a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 183-189.	1.0	84
58	Auditory involvement in Behcet's disease: relationship with demographic, clinical, and therapeutic characteristics. Clinical Rheumatology, 2017, 36, 445-449.	1.0	9
59	Adalimumab effectiveness in Behçet's disease: short and long-term data from a multicenter retrospective observational study. Clinical Rheumatology, 2017, 36, 451-455.	1.0	52
60	Psoriasis and Psoriatic Arthritis-Related Uveitis: Different Ophthalmological Manifestations and Ocular Inflammation Features. Seminars in Ophthalmology, 2017, 32, 715-720.	0.8	40
61	Update on the Medical Management of Gastrointestinal Behçet's Disease. Mediators of Inflammation, 2017, 2017, 1-11.	1.4	16
62	Cytokine Signatures in Mucocutaneous and Ocular Behçet's Disease. Frontiers in Immunology, 2017, 8, 200.	2.2	50
63	Diagnostic Criteria for Adult-Onset Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2017, 8, 1018.	2.2	37
64	Impact of Uveitis on Quality of Life: A Prospective Study from a Tertiary Referral Rheumatology-Ophthalmology Collaborative Uveitis Center in Italy. Israel Medical Association Journal, 2017, 19, 478-483.	0.1	19
65	Relationship between Corneal Temperature and Intraocular Pressure in Healthy Individuals: A Clinical Thermographic Analysis. Journal of Ophthalmology, 2016, 2016, 1-7.	0.6	14
66	A Snapshot on the On-Label and Off-Label Use of the Interleukin-1 Inhibitors in Italy among Rheumatologists and Pediatric Rheumatologists: A Nationwide Multi-Center Retrospective Observational Study. Frontiers in Pharmacology, 2016, 7, 380.	1.6	72
67	Transepithelial Iontophoresis Versus Standard Corneal Collagen Cross-linking: 1-Year Results of a Prospective Clinical Study. Journal of Refractive Surgery, 2016, 32, 672-678.	1.1	53
68	Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art. Clinical Rheumatology, 2016, 35, 2631-2638.	1.0	28
69	Local (topical and intraocular) therapy for ocular Adamantiadesâ^'Behçet's disease. Current Opinion in Ophthalmology, 2015, 26, 546-552.	1.3	11
70	Treatment of corneal neovascularization in ocular chemical injury with an off-label use of subconjunctival bevacizumab: a case report. Journal of Medical Case Reports, 2013, 7, 199.	0.4	3
71	Severe Macular Edema in Patients with Juvenile Idiopathic Arthritis-Related Uveitis. Case Reports in Ophthalmological Medicine, 2013, 2013, 1-5.	0.3	9
72	Effects of Intravitreal Bevacizumab on Inflammatory Choroidal Neovascular Membrane. European Journal of Ophthalmology, 2013, 23, 114-118.	0.7	12

#	Article	IF	CITATIONS
73	Retinal Complications of Juvenile Idiopathic Arthritis-related Uveitis: A Microperimetry and Optical Coherence Tomography Study. Ocular Immunology and Inflammation, 2010, 18, 54-59.	1.0	33
74	Corneal epithelial proliferation and thickness in a mouse model of dry eye. Experimental Eye Research, 2009, 89, 166-171.	1.2	93
75	Adalimumab for refractory idiopathic scleritis in children. Clinical and Experimental Rheumatology, 0, , .	0.4	2
76	Development and Implementation of the AIDA International Registry for Patients With Undifferentiated Systemic AutoInflammatory Diseases. Frontiers in Medicine, 0, 9, .	1.2	4